Travere Therapeutics (TVTX) revenue breakdown
By product, Net product sales is the largest at 84% of fiscal 2025 revenue; License and collaboration revenue grew fastest, 48% a year over 4 years.
Revenue by product
Fiscal years, as Travere Therapeutics reports them in its 10-K filings; fiscal 2025 total $491M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | — | — | — | — | — | $115M | $98M | $128M | $227M | $410M | 84% |
| License and collaboration revenue | — | — | — | — | — | $17M | $11M | $18M | $6M | $80M | 16% |
| Tiopronin products | — | — | — | — | $109M | — | — | — | — | — | — |
| Tiopronin products | $71M | $82M | $89M | $96M | — | — | — | — | — | — | — |
| Bile acid products | — | — | — | — | $89M | — | — | — | — | — | — |
| Bile acid products | $62M | $73M | $75M | $80M | — | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TVTX.
Open TVTX in InvestinglyQuestions
Where does Travere Therapeutics make its money?
In fiscal 2025, by product: Net product sales $410M, License and collaboration revenue $80M.
From Travere Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.